Search Results - "Coombes, Megan"

Longitudinal adherence to colorectal cancer screening guidelines by Cyhaniuk, Anissa, Coombes, Megan E

“…To describe adherence with United States Preventive Services Task Force (USPSTF) colorectal cancer (CRC) screening recommendations over a 10-year period in a…”
Get full text

Adjuvant therapy for completely resected stage II colon cancer by Figueredo, Alvaro, Coombes, Megan E, Mukherjee, Som

“…Colon cancer is potentially curable by surgery. Although adjuvant chemotherapy benefits patients with stage III disease, there is uncertainty of such benefit…”
Get more information

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer by Brezden-Masley, Christine, Fathers, Kelly E., Coombes, Megan E., Pourmirza, Behin, Xue, Cloris, Jerzak, Katarzyna J.

“…Purpose To update and expand on data related to treatment, resource utilization, and costs by cancer stage in Canadian patients with hormone receptor-positive…”
Get full text

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer by Brezden-Masley, Christine, Fathers, Kelly E., Coombes, Megan E., Pourmirza, Behin, Xue, Cloris, Jerzak, Katarzyna J.

“…Purpose We sought to expand the currently limited, Canadian, population-based data on the characteristics, treatment pathways, and health care costs according…”
Get full text

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis by Wilson, Florence R, Coombes, Megan E, Brezden-Masley, Christine, Yurchenko, Mariya, Wylie, Quinlan, Douma, Reuben, Varu, Abhishek, Hutton, Brian, Skidmore, Becky, Cameron, Chris

“…Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early…”
Get full text

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer by Brezden‐Masley, Christine, Fathers, Kelly E., Coombes, Megan E., Pourmirza, Behin, Xue, Cloris, Jerzak, Katarzyna J.

“…Background There have been few publications exploring the characteristics, treatment pathways, and health‐care costs by stage in patients with a…”
Get full text

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis by Wilson, Florence R, Coombes, Megan E, Wylie, Quinlan, Yurchenko, Mariya, Brezden-Masley, Christine, Hutton, Brian, Skidmore, Becky, Cameron, Chris

“…Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive disease that makes up about 20% of all invasive breast cancers. HER2+…”
Get full text

A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials by Mukherjee, Som D., Coombes, Megan E., Levine, Mitch, Cosby, Jarold, Kowaleski, Brenda, Arnold, Andrew

“…Summary Background In early phase oncology trials, novel targeted therapies are increasingly being tested in combination with traditional agents creating…”
Get full text

Examination for Sexual Assault: Evaluating the Literature for Indicators of Women-Centered Care by McGregor, Margaret J., Mont, Janice Du, White, Deborah, Coombes, Megan E.

“…This study aimed to assess the extent to which recent peer-reviewed published literature on the acute management of sexual assault was women-centered. We…”
Get full text

Abstract PS9-55: Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis by Sripada, Kaushik, Manjrekar, Siddhi, Klein-Panneton, Kristoph, Coombes, Megan, Ferrario, Cristiano

“…Background: Recently, the FeDeriCa trial investigated a fixed-dose combination (FDC) of Perjeta and Herceptin (PH), administered by subcutaneous (SC)…”
Get full text

Abstract P2-08-23: A population-based study examining the epidemiology, treatment patterns and resource utilization by stage in Ontario patients with HER2+ breast cancer by Brezden-Masley, Christine, Fathers, Kelly Elizabeth, Coombes, Megan, Xue, Cloris, Pourmirza, Behin, Jerzak, Katarzyna J.

“…Background: Since the discovery of HER2-targeted treatments for HER2+ breast cancer (BC), women with this historically poor-prognosis subtype have benefitted…”
Get full text

Abstract P6-13-02: Subcutaneous trastuzumab for the treatment of HER2+ breast cancer in Canada: A cost-minimization study by Coombes, Megan, Yin, Lori, Liu, Ingrid, Shek, Norman, Rusu, Flavia, Mukherjee, Som

“…Background: There is an urgent need to alleviate the pressure on healthcare resources and decrease treatment burden for patients. Recently, a new fixed dose…”
Get full text

Abstract P2-08-08: A population-based study examining the epidemiology, treatment patterns and resource utilization by stage in Ontario patients with triple negative breast cancer by Brezden-Masley, Christine, Fathers, Kelly Elizabeth, Coombes, Megan, Xue, Cloris, Pourmirza, Behin, Jerzak, Katarzyna J.

“…Background: There is limited current data on the incidence, clinical characteristics, treatment patterns, and resource utilization in breast cancer patients…”
Get full text

Does antibiotic exposure during infancy lead to development of asthma?: a systematic review and metaanalysis by Marra, Fawziah, Lynd, Larry, Coombes, Megan, Richardson, Kathryn, Legal, Michael, Fitzgerald, J Mark, Marra, Carlo A

“…To determine the association between antibiotic exposure in the first year of life and the development of childhood asthma. Metaanalysis of observational…”
Get more information

Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs? by Coombes, Megan E, Morgan, Steven G, Barer, Morris L, Pagliccia, Nino

“…Public prescription drug plans vary markedly across Canada. To address perceived inequities in coverage across provinces, the February 2003 First Ministers'…”
Get more information

Income-Based Drug Coverage in British Columbia: Towards an Understanding of the Policy by Morgan, Steve, Coombes, Megan

“…Background and Objectives In May 2003, the government of British Columbia adopted income-based pharmacare, replacing an age-based drug benefits program…”
Get full text

O-6-D04/1793/Comparison of the HUI-3 and SF-6D in Patients with Latent and Active Tuber-Culosis by Carlo A. Marra, Megan E. Coombes, Susanne Moadebi, Eugenia Yeh, J. Mark Fitz Gerald, Kevin Elwood, Brazier, John E., Fawziah Marra

Get full text